For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

Only men with prostate tumors of the luminal B subtype benefited from adding apalutamide to salvage radiation in the phase 2 ...

Until about 15 years ago, most men diagnosed with prostate cancer — no matter how aggressive — underwent surgery or radiation ...

A UCLA study shows that a new treatment combining radioactive drug with radiation therapy could help delay hormone therapy ...

In an analysis of more than half a million men with hypogonadism, testosterone replacement therapy is tied to a 16% lower prostate cancer risk and a 13% higher benign prostatic hyperplasia risk.

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits ...

Recurrent prostate cancer patients with luminal B tumors may benefit from hormone therapy added to radiation following surgery.

A shorter radiation course improved quality of life among men with intermediate-risk, localized prostate cancer, according to ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...

SGMC Health now offers PLUVICTO, a cutting-edge therapy for men diagnosed with metastatic castration-resistant prostate ...

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that stereotactic body radiotherapy (SBRT) ...

Imagine a future where the moment you’re born, a virtual avatar is created and steadily filled with personalised information ...